2. Academic Validation
  3. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma

The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma

  • Br J Cancer. 2023 Oct 26. doi: 10.1038/s41416-023-02464-y.
Zhijian Kuang # 1,  Kaiqiang Guo # 1 2,  Yin Cao # 1,  Mengxue Jiang # 3,  Chaojie Wang 1 4,  Qiaoqiong Wu 1,  Guosheng Hu 1,  Mingtao Ao 1,  Mingfeng Huang 1,  Jingbo Qin 1,  Taige Zhao 1,  Sheng Lu 1,  Cuiling Sun 1,  Mingyu Li 1,  Tong Wu 5,  Wen Liu 6,  Meijuan Fang 7
Affiliations

Affiliations

  • 1 Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, 361102, Xiamen, China.
  • 2 College of Arts, Sichuan University, 610207, Chengdu, China.
  • 3 School of Medicine, Xiamen University, 361102, Xiamen, China.
  • 4 Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical Colloge), 519 East Beijing Rd, 330029, Nanchang, Jiangxi, China.
  • 5 Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, 361102, Xiamen, China. tongywu@gmail.com.
  • 6 Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, 361102, Xiamen, China. w2liu@xmu.edu.cn.
  • 7 Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, 361102, Xiamen, China. fangmj@xmu.edu.cn.
  • # Contributed equally.
PMID: 37884683 DOI: 10.1038/s41416-023-02464-y
Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is a highly lethal malignancy with few therapeutic options. Cyclin‑dependent kinase 9 (CDK9), a potential therapeutic target of many cancers, has been recently observed to be upregulated in ccRCC patients. Therefore, we aimed to investigate the therapeutic potential of CDK9 in ccRCC and develop a novel CDK9 Inhibitor with low toxicity for ccRCC treatment.

Methods: The expression of CDK9 in ccRCC was checked using the online database and tissue microarray analysis. shRNA-mediated CDK9 knockdown and CDK Inhibitor were applied to evaluate the effect of CDK9 on ccRCC. Medicinal chemistry methods were used to develop a new CDK9 Inhibitor with drugability. RNA-seq and ChIP-seq experiments were conducted to explore the mechanism of action. MTS, western blotting, and colony formation assays were performed to evaluate the anti-ccRCC effects of CDK9 knockdown and inhibition in vitro. The in vivo anti-tumour efficacy was evaluated in a xenograft model.

Results: CDK9 is overexpressed and associated with poor survival in ccRCC. Knockdown or inhibition of CDK9 significantly suppressed ccRCC cells. XPW1 was identified as a new potent and selective CDK9 Inhibitor with excellent anti-ccRCC activity and low toxicity. In mechanism, XPW1 transcriptionally inhibited DNA repair programmes in ccRCC cells, resulting in an excellent anti-tumour effect. CDK9 and BRD4 were two highly correlated transcriptional regulators in ccRCC patients, and the BRD4 Inhibitor JQ1 enhanced XPW1's anti-ccRCC effects in vitro and in vivo.

Conclusions: This work provides valuable insights into the therapeutic potential of CDK9 in ccRCC. The CDK9 Inhibitor XPW1 would be a novel therapeutic agent for targeting ccRCC, alone or in rational combinations.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-149673
    99.27%, CDK9 Inhibitor
    CDK